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ABSTRACT
Background In patients with acquired heart failure,
hypoalbuminaemia is associated with increased risk of
death. The prevalence of hypoproteinaemia and
hypoalbuminaemia and their relation to outcome in
adult patients with congenital heart disease (ACHD)
remains, however, unknown.
Methods Data on patients with ACHD who underwent
blood testing in our centre within the last 14 years were
collected. The relation between laboratory, clinical or
demographic parameters at baseline and mortality was
assessed using Cox proportional hazards regression
analysis.
Results A total of 2886 patients with ACHD were
included. Mean age was 33.3 years (23.6–44.7) and
50.1% patients were men. Median plasma albumin
concentration was 41.0 g/L (38.0–44.0), whereas
hypoalbuminaemia (<35 g/L) was present in 13.9% of
patients. The prevalence of hypoalbuminaemia was
signiﬁcantly higher in patients with great complexity
ACHD (18.2%) compared with patients with moderate
(11.3%) or simple ACHD lesions (12.1%, p<0.001).
During a median follow-up of 5.7 years (3.3–9.6), 327
(11.3%) patients died. On univariable Cox regression
analysis, hypoalbuminaemia was a strong predictor of
outcome (HR 3.37, 95% CI 2.67 to 4.25, p<0.0001).
On multivariable Cox regression, after adjusting for age,
sodium and creatinine concentration, liver dysfunction,
functional class and disease complexity,
hypoalbuminaemia remained a signiﬁcant predictor of
death.
Conclusions Hypoalbuminaemia is common in patients
with ACHD and is associated with a threefold increased
risk of risk of death. Hypoalbuminaemia, therefore,
should be included in risk-stratiﬁcation algorithms as it
may assist management decisions and timing of
interventions in the growing ACHD population.
INTRODUCTION
The number of adult patients with congenital heart
disease (ACHD) is increasing. Despite ongoing
research and continuous improvement in care in
what is increasingly recognised as a condition with
multiorgan involvement, mortality remains consid-
erable.1 Risk stratiﬁcation is an essential component
of the management of patients with ACHD, and
identiﬁcation of parameters, both cardiac and non-
cardiac, strongly related to outcome is crucial.2–4
Hypoalbuminaemia is a marker of liver and renal
dysfunction, but also advanced cardiovascular
disease, subclinical systemic inﬂammation and
endothelial dysfunction.5 Albumin is the most
abundant protein in plasma and the main determin-
ant of plasma oncotic pressure. It counterbalances
hydrostatic pressure and controls ﬂuid distribution
in body compartments. Moreover, albumin affects
the pharmacokinetics of many drugs, thus, modu-
lating response to treatment. Hence, hypoalbumi-
naemia may result or contribute to pulmonary or
peripheral congestion, inﬂuence pharmacological
therapy and, ultimately, mortality in ACHD.6
Hypoalbuminaemia has been reported in selected
subgroups of patients with ACHD, but the preva-
lence of hypoalbuminaemia and its relation to
outcome across the spectrum of patients with
ACHD remains unknown.
We sought to examine the prevalence and prog-
nostic signiﬁcance of hypoalbuminaemia in a large
single-centre cohort of patients with ACHD.
PATIENTS AND METHODS
This was a retrospective cross-sectional study. Data
on all patients with ACHD under active follow-up
at our institution since 2000 were retrieved and
studied. Adult patients who had albumin levels
assessed at our institution were enrolled in the
study; when multiple tests were performed, the ﬁrst
test during the study period was included and
analysed.
Albumin was assessed in all patients hospitalised
in our institution, in patients undergoing routine,
periodic comprehensive 1-day assessment (day case
assessment), as well as in the outpatient clinic
setting mainly in symptomatic patients and those
on heart failure or other treatments. Over the last
several years, albumin levels were also routinely
assessed in patients with Fontan-type circulation
and in patients with cyanotic heart disease with or
without pulmonary arterial hypertension.
For the scope of this study, we deﬁned the start
of adulthood as age of ≥16 years. Demographic
and clinical data were obtained from our dedicated
clinical database and the patient’s clinical records.
Mortality data were retrieved from the national
database.
Patients were grouped by primary diagnosis into
major ACHD groups. Moreover, they were classi-
ﬁed according to ACHD complexity based on the
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Bethesda Conference classiﬁcation.7 Estimated survival and stan-
dardised mortality ratio for an age-matched and gender-matched
cohort was based on the Interim Life Tables for England and
Wales (2007–2009) published by the Government Actuary’s
Department. Total serum protein and albumin were measured
on the Beckman DxC600 or LX20 analyser (Beckman Coulter,
High Wycombe, UK). Albumin was measured by a timed end-
point method at 600 nm using bromocresol purple, and total
protein was measured by a timed endpoint biuret method at
560 nm.
STATISTICAL ANALYSIS
Statistical analyses were performed using R-package V.3.0.2 for
Windows and MedCalc for Windows, V.11.6.1.0 (MedCalc
Software, Mariakerke, Belgium).8 Continuous variables are pre-
sented as mean±SD or median and IQR, shown in parentheses,
depending on data distribution. Categorical variables are pre-
sented as number (percentage). Data distribution was assessed
for normality using the Shapiro–Wilk test. In case of normally
distributed variables, comparison between groups was per-
formed using unpaired two-tailed t test or Welch test in case of
unequal variances. For data demonstrating a non-normal distri-
bution, Mann–Whitney test was used. Differences in continuous
variables between multiple groups were assessed using one-way
analysis of variance. Categorical variables were compared using
χ2 test. Predictors of hypoalbuminaemia were identiﬁed using
logistic regression analysis. The relation between hypoalbumi-
naemia and other clinical and demographic parameters to mor-
tality was assessed using Cox proportional hazards regression
analysis.
Threshold analysis for albumin is presented as a functional
form of the unadjusted relationship between plasma albumin
concentration and the hazard of death and is plotted using term-
plot function in R. Unadjusted Kaplan–Meier survival curves
were also plotted and the difference in survival between patients
with and without hypoalbuminaemia was assessed using the
log-rank test. Sensitivity analysis was performed after exclusion
of serum albumin measured during infection (clinical signs of
infection or C-reactive protein (CRP) >20 mg/dL or white
blood cells >107/mL) or within 2 weeks postcardiac surgery or
percutaneous intervention. Also, as serum albumin concentra-
tion may have changed over the study period, we have per-
formed a sensitivity analysis using all values recorded in each
patient during study period and albumin analysed as a time-
dependent covariate in the Cox regression model. A two-sided p
value of <0.05 was considered indicative of statistical
signiﬁcance.
RESULTS
Demographics
In total, 2886 patients with ACHD were included in the ana-
lysis. Demographic and clinical characteristics are presented in
tables 1 and 2. Mean age at baseline was 33.3 (23.6–44.7)
years, and 50.1% of patients were men. Data on serum creatin-
ine, sodium or liver status (aspartate transaminase (AST) or
alanine transaminase (ALT)) were available in 99% of patients.
The largest diagnostic groups were patients with valve or left or
right outﬂow tract disease (n=518), atrial septal defect (n=479)
and tetralogy of Fallot (n=474). When classiﬁed according to
the severity of the underlying congenital defect (using the
Bethesda classiﬁcation), 1223 (42.4%) patients had simple, 976
(33.8%) moderate and 687 (23.8%) great complexity ACHD.
The majority of patients were asymptomatic (New York Heart
Association (NYHA) functional class I in 57.1%, II in 34.9%
and III/IV in 8.0%).
Albumin, total protein and liver dysfunction
Median albumin and protein concentration was 41.0 (38.0–44.0)
and 70.0 (66.0–74.0), respectively (table 1). Overall, hypoalbumi-
naemia (<35 g/L) was present in 13.3% of patients and hypopro-
teinaemia (<60 g/L) in 8.0%. Hypoproteinaemia was almost
always associated with hypoalbuminaemia, with only 0.38% of
patients presenting with hypoproteinaemia but no hypoalbumi-
naemia. The prevalence of hypoalbuminaemia was signiﬁcantly
higher in patients with great complexity ACHD (18.2%) com-
pared with patients with moderate (11.3%) or simple ACHD
(12.1%, p<0.001). Hypoalbuminaemia was most common in
patients with Eisenmenger syndrome (26.6%) and the complex
ACHD subgroup (single-ventricle physiology without evidence of
pulmonary hypertension, 18.6%) and lowest in patients with
aortic coarctation (9.0%, p<0.001 for comparison across diagnos-
tic groups, ﬁgure 1). In contrast, there was no signiﬁcant difference
in the prevalence of hypoproteinaemia between subgroups of
disease severity (great complexity ACHD 7.1%, moderate 8.0%,
simple ACHD 8.5%, p=0.57).
Abnormal AST (>34 U/L) or ALT (>40 U/L), suggestive of
liver dysfunction, was encountered in 10.4% of patients. Only
17.5% of patients with hypoalbuminaemia had elevated AST or
ALT, whereas 74% of patients with elevated AST or ALT had
both normal serum albumin and protein.
Mortality and predictors of outcome
During a median follow-up of 5.7 years (cumulative follow-up
time of 18 503 patient-years), 327 (11.3%) patients died. On
Kaplan–Meier statistics, 1-year, 5-year and 10-year mortality for
the entire study population was 2.8% (95% CI 2.2% to 3.4%),
8.1% (95% CI 7.1% to 9.2%) and 15.9% (95% CI 14.1% to
17.7%), respectively. Overall mortality was signiﬁcantly higher
compared with age-matched and gender-matched UK popula-
tion (standardised mortality ratio 4.03, 95% 3.56 to 4.56,
p<0.001). Within the study period, 2886 patients had at least
one measurement of serum albumin, while 2292 patients, being
44% of all patients attending the outpatient clinic in the study
period, had no serum albumin assessment. Patients with ‘simple
ACHD’ in whom albumin had been assessed during the study
period had a higher mortality on multivariable Cox regression
analysis (including age and functional class) compared with
those with no albumin assessment (HR 1.68, 95% CI 1.08 to
2.64, p=0.023). However, this was not true for patients with
ACHD with moderate disease complexity (HR 1.50, 95% CI
0.81 to 2.80, p=0.2) or high-disease complexity (HR 1.85,
95% CI 0.93 to 3.67, p=0.08).
On univariable Cox regression analysis, hypoalbuminaemia
(serum albumin <35 g/L) was related to a more than threefold
increased risk of death (HR 3.37, 95% CI 2.67 to 4.25,
p<0.001; ﬁgures 2 and 3). A twofold increased risk of death was
also identiﬁed for patients with hypoproteinaemia (HR 2.24,
95% CI 1.66 to 3.01, p<0.001). When albumin was analysed as
a continuous variable, a twofold increase in risk was identiﬁed
for each 10 g/L decrease in albumin concentration (HR 2.08,
95% CI 1.82 to 2.38, p<0.001). As a sensitivity analysis, using
multiple values of albumin over time in a repeated-measures Cox
regression model, albumin remained a strong predictor of
outcome as well (HR 2.26 per 10 g/L decrease, 95% CI 1.97 to
2.60, p<0.001).
Threshold analysis revealed no clear cut-off for albumin in rela-
tion to mortality, with decreasing albumin levels associated with an
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ever-increasing risk of death (ﬁgure 4). Hypoalbuminaemia was a
strong predictor of outcome in each of the three groups of diagnos-
tic severity: HR 2.29, 95% CI 1.45 to 3.60 for simple ACHD; HR
3.66, 95% CI 2.21 to 6.05 for moderate ACHD; HR 3.51, 95%
CI 2.83 to 4.87 for great complexity ACHD, p<0.001 for all.
Several other variables emerged as predictors of death (ﬁgure 3),
including older age, higher ACHD complexity and higher func-
tional class. Other biochemical parameters related to mortality
included hyponatraemia and a high serum creatinine. In contrast,
liver dysfunction was not predictive of outcome. On a bivariate
analysis, including hypoalbuminaemia and hypoproteinaemia, only
hypoalbuminaemia remained in the model, suggesting a stronger
relationship of hypoalbuminaemia to outcome than hypoproteinae-
mia. On multivariable Cox regression analysis, including all uni-
variable predictors, hypoalbuminaemia remained in the model
with age, functional class, creatinine and sodium concentration
(HR for hypoalbuminaemia 1.96, 95% CI 1.48 to 2.59, p<0.001).
The same was true for albumin used as a continuous variable (HR
1.61 per 10 g/L decrease of albumin, 95% CI 1.33 to 1.95,
p<0.001). As a sensitivity analysis, in order to exclude any effect of
inﬂammation or haemodilution on the relation between albumin
and mortality, all albumin values associated with a CRP >20 mg/
dL or white blood cells count >107/mL as well as values measured
within 2 weeks of surgery or percutaneous cardiac intervention
were excluded and the multivariable analysis was repeated.
Albumin remained a signiﬁcant predictor of mortality (HR 1.96
per 10 g/L decrease of albumin, 95% CI 1.56 to 2.47, p<0.001).
When the multivariable analysis was repeated considering each
ACHD complexity subgroup separately, albumin was a signiﬁcant
independent predictor of death in patients with moderate or great
ACHD complexity, while a trend was present for simple ACHD
(p=0.063).
Table 1 Baseline parameters and outcome results in all patients and subgroups according to Bethesda classification of disease complexity
ACHD group
Parameter
All patients
(n=2886)
Simple lesions
(n=1223)
Moderate complexity
(n=976)
Great complexity
(n=687)
Age 33.3 (23.6 to 44.7) 37.8 (26.6 to 51.8) 31.1 (22.2 to 42.5) 30.4 (22.8 to 38.8)
Male gender 1445 (50.1%) 610 (49.9%) 528 (54.1%) 307 (44.7%)
NYHA I 57.1% 66.7% 67.5% 28.4%
NYHA II 34.9% 28.4% 29.3% 52.3%
NYHA III/IV 8.0% 4.9% 3.2% 19.3%
Hypoalbuminaemia (n/%) 383 (13.3%) 148 (12.1%) 110 (11.3%) 125 (18.2%)
ALT (U/L) 21.0 (16.0 to 29.0) 21.0 (16.0 to 28.0) 21.0 (16.0 to 30.0) 22.0 (17.0 to 30.0)
AST (U/L) 27.0 (22.0 to 34.0) 27.0 (22.0 to 33.0) 26.0 (22.0 to 34.0) 28.0 (23.0 to 34.0)
Sodium (mmol/L) 138.0 (137.0 to 140.0) 138.0 (137.0 to 140.0) 138.0 (137.0 to 140.0) 138.0 (136.0 to 139.0)
Creatinine (μmol/L) 77.0 (66.0 to 90.0) 77.0 (64.0 to 90.0) 77.0 (66.0 to 89.0) 79.0 (67.0 to 92.0)
Haemoglobin (g/dL) 14.3 (13.1 to 15.6) 13.8 (12.7 to 15.0) 14.2 (13.0 to 15.3) 16.2 (14.2 to 19.0)
Follow-up time 5.7 (3.3 to 9.6) 5.6 (3.5 to 9.1) 5.6 (3.2 to 10.1) 5.9 (3.2 to 10.1)
Deaths 327 101 71 155
SMR for albumin≥35 g/L 3.37 (2.90 to 3.92) 1.77 (1.37 to 2.29) 3.08 (2.24 to 4.23) 14.82 (11.78 to 18.64)
SMR for albumin<35 g/L 6.80 (5.47 to 8.46) 2.53 (1.62 to 3.95) 5.10 (3.18 to 8.19) 46.31 (34.54 to 62.09)
ACHD, adult congenital heart disease; ALT, alanine transaminase; AST, aspartate transaminase; NYHA, New York Heart Association; SMR, standardised mortality ratio.
Table 2 Supplementary information on patients by leading ACHD diagnosis
NYHA
ACHD group n
Age
(years)
Male gender
n (%) I (%) II (%) ≥III (%) Follow-up (years)
Aortic coarctation 266 29.6 (21.7 to 41.0) 150 (56.4%) 85.60 13.40 1.00 6.7 (3.5 to 10.7)
Atrial septal defect 479 44.0 (31.1 to 58.6) 181 (37.8%) 63.00 33.00 4.00 5.9 (4.0 to 9.0)
Atrioventricular septal defect 113 37.5 (25.9 to 49.0) 47 (41.6%) 59.80 36.10 4.10 6.8 (3.7 to 9.7)
CCTGA 63 35.7 (24.6 to 45.2) 32 (50.8%) 43.80 35.40 20.80 5.6 (2.7 to 8.8)
Complex ACHD 172 29.0 (22.5 to 37.6) 83 (48.3%) 29.00 60.70 10.30 5.5 (2.9 to 9.7)
Ebstein anomaly 86 40.2 (29.3 to 49.9) 42 (48.8%) 48.40 40.30 11.30 5.1 (3.2 to 7.6)
Eisenmenger syndrome 259 33.6 (25.7 to 42.4) 96 (37.1%) 4.80 57.20 38.00 6.1 (3.2 to 9.0)
Fontan palliation 110 24.1 (20.0 to 31.9) 55 (50.0%) 44.10 52.70 3.20 6.7 (3.8 to 10.8)
Other ACHD 261 29.7 (21.2 to 40.8) 148 (56.7%) 72.40 23.10 4.50 4.8 (2.9 to 9.0)
Postatrial switch for TGA 85 28.9 (22.9 to 32.6) 43 (50.6%) 64.80 32.40 2.80 6.4 (3.5 to 12.1)
Tetralogy of Fallot 474 30.8 (22.2 to 40.8) 263 (55.5%) 62.60 34.40 3.00 5.4 (3.3 to 9.9)
Valve/outflow disease 518 36.4 (25.1 to 48.3) 305 (58.9%) 67.60 26.80 5.60 5.3 (3.4 to 9.3)
Total 2886 33.3 (23.6 to 44.7) 1445 (50.1%) 57.10 34.90 8.00 5.7 (3.3 to 9.6)
The ‘Complex ACHD’ subgroup includes single-ventricle physiology patients without evidence of pulmonary hypertension. Patients classified as ‘other ACHD’ are patients with restrictive
ventricular septal defects, repaired persistent ductus arteriosus, Marfan syndrome or patients with TGA after arterial switch.
ACHD, adult congenital heart disease; CCTGA, congenitally corrected transposition of the great arteries; NYHA, New York Heart Association; TGA, transposition of the great arteries.
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Predictors of hypoalbuminaemia
On univariable logistic regression analysis, several variables emerged
as signiﬁcant risk factors for hypoalbuminaemia (ﬁgure 5). These
included age (OR 1.11 per 10 years, 95% CI 1.04 to 1.19,
p=0.003), complex ACHD (OR 1.67, 95% CI 1.33 to 2.11,
p<0.001) and functional class (OR 2.42 for patients in NYHA III/IV,
95% CI 1.68 to 3.48, p<0.001, ﬁgure 6). Liver dysfunction (deﬁned
as elevated ASTor ALT, OR 2.41, 95% CI 1.79 to 3.26, p<0.001)
and renal dysfunction (deﬁned as creatinine >120 mmol/L, OR 3.82,
95% CI 2.60 to 5.61, p<0.001) were also predictors of
hypoalbuminaemia. On multivariable logistic regression including all
univariable predictors, only functional class and presence of liver or
renal dysfunction remained in the model. The abstract with the main
results has been presented at the European Society of Cardiology
Congress 2014 in Barcelona and has been printed in the congress
abstract book.
DISCUSSION
Our study demonstrates for the ﬁrst time that hypoalbuminae-
mia is common across the spectrum of ACHD and is a strong
independent predictor of mortality. Increased awareness of this
simple, often neglected risk factor may help to improve risk
assessment in this expanding population of patients.
Hypoalbuminaemia appeared to be a stronger predictor of
outcome in patients with moderate to complex ACHD, who are
at risk of adverse events and, thus, are more likely to beneﬁt
from accurate risk stratiﬁcation algorithms.
The pathogenesis of hypoalbuminaemia in patients with
ACHD
The aetiology of hypoalbuminaemia in ACHD is likely to be
multifactorial. Hypoalbuminaemia has previously been reported
in patients with both acute and chronic heart failure due to sys-
tolic or diastolic LV dysfunction, in the setting of acquired heart
disease.9 10 Venous congestion is known to contribute to an
increased transcapillary escape rate of albumin (TER), that is,
the fraction of intravascular mass of albumin that passes to the
extravascular space per unit of time. TER is signiﬁcantly
increased in patients with congestive heart failure and a raised
central venous pressure, and the same is likely to be true in
patients with ACHD.11 In fact, evidence of raised central
venous pressure has been reported in various ACHD cohorts,
including patients with Eisenmenger syndrome, Fontan circula-
tion and tetralogy of Fallot.12 13 Surprisingly in our cohort,
patients with a Fontan-type circulation, in whom central venous
hypertension is the norm, had a relatively low prevalence of
hypoalbuminaemia, suggesting that other mechanisms, beyond a
high central venous pressure, are promoting hypoalbuminaemia.
Recent studies have shown that chronic systemic inﬂammation
and endothelial dysfunction play an even more important role
than venous congestion in promoting albumin loss to the extra-
vascular space in acquired heart failure.14 Inﬂammation and
endothelial dysfunction have been reported in various ACHD
groups, including patients with repaired aortic coarctation, tet-
ralogy of Fallot and single-ventricle physiology.15–17 In patients
with Eisenmenger syndrome, the group with the highest preva-
lence of hypoalbuminaemia in our cohort, evidence of signiﬁ-
cant endothelial dysfunction and chronic, subclinical
inﬂammation with CRP activation has been described recently
Figure 1 Prevalence of hypoalbuminaemia by adult congenital heart
disease (ACHD) diagnosis. Bar width is in proportion to the number of
patients in each group. Whiskers represent the SE of the prevalence
estimate. CCTGA, congenitally corrected transposition of the great
arteries; TGA, transposition of the great arteries.
Figure 2 Kaplan–Meier survival curves in patients with adult
congenital heart disease by serum albumin. The numbers bellow the
horizontal axis represent the number of patients at risk.
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and is likely to be contributing to increased vascular permeabil-
ity with enhanced albumin catabolism.18 19
The association between hypoalbuminaemia and raised liver
enzymes in our cohort also suggests a role for decreased
albumin synthesis rates in its pathogenesis. However, the vast
majority (82.5%) of patients presenting with hypoalbuminaemia
had no evidence of liver dysfunction. In fact, primary liver dys-
function is rarely the sole reason for hypoalbuminaemia in the
general population.20 Furthermore, patients with Fontan circula-
tion, in whom both an increased hydrostatic venous pressure
and an increased incidence of liver dysfunction are present,21
the prevalence of hypoalbuminaemia in our series was relatively
low (9.1%) compared with other ACHD subgroups. This may
suggest that endothelial dysfunction and chronic inﬂammation
are stronger drivers for hypoalbuminaemia in the ACHD cohort
than hepatic dysfunction or raised hydrostatic pressure.
Finally, hypoalbuminaemia may also be caused by albumin-
uria. A high prevalence of renal dysfunction has been described
previously in patients with ACHD, especially those with more
complex disease and those with Eisenmenger syndrome, in
whom there is also a high prevalence of hypoalbuminaemia.2
Moreover, renal dysfunction was a strong independent predictor
of hypoalbuminaemia in our cohort.
The association between hypoalbuminaemia and outcome
Hypoalbuminaemia likely relates to mortality in the ACHD
population through various mechanisms. Preoperative hypoalbu-
minaemia is a recognised risk factor for perioperative mortality,
infection, ventilator dependency and long-term mortality, both
for cardiac and non-cardiac surgery.22–25 Many patients with
ACHD require one or more surgeries during their lifetime, and
hypoalbuminaemia contributes to perioperative morbidity and
mortality. It has been proposed that this effect may be, at least
in part, related to the high antioxidative properties of
albumin.26 27 Moreover, hypoalbuminaemia is directly related
to lower serum osmotic pressure28 and can promote peripheral
and pulmonary congestion, which can be potentially lethal.
However, it is more likely that hypoalbuminaemia is an indica-
tor of multiorgan derangement, including cardiac, renal and
liver disease, which are associated with a higher likelihood of
adverse outcome. Moreover, low albumin levels may reﬂect gen-
eralised endothelial dysfunction, inﬂammation and possibly neu-
rohormonal activation, which again adversely affect survival.
Hypoalbuminaemia was a predictor of mortality independent of
creatinine levels and sodium concentration, suggesting that it
carries prognostic information beyond renal dysfunction or neu-
rohormonal activation (an established driver for hyponatraemia
in heart failure).
Clinical implications
ACHD physicians have in the past focused their attention on
hypoalbuminaemia mainly in the setting of protein losing enter-
opathy in patients with a failing Fontan circulation.29 30 In the
light of the present study, screening for hypoalbuminaemia
should be included in the routine blood test panel of all patients
with ACHD, not only those with more complex defects or
Figure 3 Results of univariable Cox
proportional hazard regression analysis
for overall mortality. ACHD, adult
congenital heart disease; ALT, alanine
transaminase; AST, aspartate
transaminase; NYHA, New York Heart
Association.
Figure 4 Threshold analysis for plasma albumin presented as
functional form of the unadjusted relationship between plasma albumin
concentration and the hazard of death and 95% CIs using smoothing
splines.
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signiﬁcant symptoms. Patients with hypoalbuminaemia should
be deemed at increased risk of death, and potential causes of
hypoalbuminaemia should be examined. Hypoalbuminaemia in
this setting is a robust, unifying parameter with sound patho-
physiological background and should be an integral part of the
decision making in this complex group of patients.
Limitations
This is a retrospective study performed in a single, large, tertiary
adult congenital heart centre. The prevalence of hypoalbumi-
naemia in our study reﬂects the case-mix of patients with
ACHD seen in a tertiary centre such as ours, with a high pro-
portion of patients with moderate or severe lesions. Moreover,
prevalence estimates are likely to be inﬂuenced by a referral
bias, as not all patients with ACHD over the study period under-
went blood sampling.
In fact, patients in whom albumin had not been assessed
during the study period were less likely to present with hypoal-
buminaemia, but also had lower mortality. This suggests that
even though referral bias may have affected our estimates of the
prevalence of hypoalbuminaemia, especially in patients with
simple forms of ACHD, it is unlikely to have affected the strong
prognostic value of hypoalbuminaemia reported in our study.
Neither ALT nor ASTare optimal markers of liver dysfunction
and liver imaging, or in selected cases biopsy, provide better
insight into hepatic function.
Figure 5 Results of univariable
logistic regression analysis for the
presence of hypoalbuminaemia. Liver
dysfunction is deﬁned as elevated serum
aspartate transaminase (>34 U/L) or
alanine transaminase (>40 U/L); renal
dysfunction is deﬁned as serum
creatinine >120 mmol/L. NYHA,
New York Heart Association.
Figure 6 Distribution of serum albumin concentration by New York
Heart Association (NYHA) functional class group. The box and whiskers
represent the 10th, 25th, 50th, 75th and the 90th centile of serum
albumin content. There is a signiﬁcant difference in serum albumin
concentration between groups (analysis of variance p<0.0001).
Key messages
What is already known on this subject?
Risk stratiﬁcation is essential in the management of adult
patients with congenital heart disease (ACHD), and
identiﬁcation of parameters related to outcome is crucial.
Hypoalbuminaemia has been reported in subgroups of patients
with ACHD, but its prevalence and relation to mortality across
the spectrum of patients with ACHD was unknown.
What might this study add?
Our study demonstrates that hypoalbuminaemia is common in
patients with ACHD. The prevalence of hypoalbuminaemia is
highest in patients with Eisenmenger syndrome (27%) and
complex ACHD (19%). Surprisingly, however, the prevalence of
hypoalbuminaemia in patients with Fontan circulation in our
cohort was relatively low (9%). Hypoalbuminaemia was a strong
predictor of mortality associated with a threefold increased risk
of death, also after adjustment for disease complexity,
functional class and other risk factors.
How might this impact on clinical practice?
This study facilitates interpretation of serum albumin status and
risk stratiﬁcation in patients with CHD. Patients identiﬁed with
hypoalbuminaemia are at increased risk of death. They require,
therefore, additional investigations to identify the reason for
decreased serum albumin and, potentially, may beneﬁt from
intensiﬁed treatment to modulate their increased risk of
mortality.
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Future, larger prospective studies are clearly warranted to
further investigate the mechanisms linking hypoalbuminaemia
to outcome in ACHD and its place in a holistic risk assessment
algorithm in this unique and challenging group of patients.
CONCLUSIONS
Hypoalbuminaemia is common in patients with ACHD and is a
strong, independent predictor of mortality associated with an
over threefold increased risk of death. Plasma albumin concen-
tration should be a part of the routine assessment of patients
with ACHD, and unexplained hypoalbuminaemia, even in clin-
ically stable and oligosymptomatic patients, should trigger
appropriate measures to identify underlying causes of serum
albumin imbalance, but more importantly lead to closer moni-
toring and measures aimed at improving prognosis.
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